Bertis Inc.
Address : 3rd floor, B Building, 33, Gwacheon-daero 7-gil, Gwacheon-si, Gyeonggi-do, Republic of Korea
General : contact@bertis.comIR : ir@bertis.comMedia : communication@bertis.com
Panomics Analysis Service & Solution
PASS
PASS is an analysis solution optimized for academia and pharma research.
The proprietary solution was derived from proven technology and innovation
embedded in Mastocheck, a proteomics-based early cancer diagnostics approved
by Ministry of Food and Drug Safety (MFDS).
PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than 15 years in mass spectrometry and integrated data interpretation.
Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable.
PASS not only provides frontier biological systems research based on top-tier expertise and leading edge infrastructure and equipment, allows you to reduce resources and increase success rate associated with clinical trials.
With PASS, you can leverage Bertis’ scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.
Service Brochure
We identify various proteins within different samples using mass spectrometry-based methods and analyze quantitative changes to provide protein information associated with specific diseases or conditions.
PASS offers optimized services tailored to the needs of our customers using the ProteoID platform, including COFFER, BTS MS, BTS Reads, and BTS Systems.
biomarker discovery, drug target discovery, PTM analysis, pharmaceutical CMC quality control
(exosome, PROTAC), characterization and process analysis of protein therapeutics (ADC, HCP)
Provide analysis of PTMs (Post-Translational Modifications) in proteins that are difficult to interpretaste through RNA information.
Quantitative analysis of modified proteins and amino acids for the major in vivo PTMs (Phosphorylation, Acetylation, Methylation, Ubiquitination, Glycosylation).
Quality control (QC) of novel drug modality such as exosomes and TPD (Targeted Protein Degradation; PROTAC)
Provide information for quality management to ensure equivalence and compliance to the ‘Development of Production Process and Quality Control Guidelines for Exosome-Based Therapeutics’ provided by the Ministry of Food and Drug Safety.
Analysis package: Comparative profiling of proteins, lipids, and RNA
Provide the quantitative results of target protein degradation and regulation of downstream pathway
proteins in response to drug treatment.
Bioinformatics analysis to elucidate the impact of off-target proteins. This approach allows us to under
stand the effects exerted on off-target proteins in a comprehensive manner.
Analysis package: Proteomics and bioinformatics analysis
PASS provides accurate quantitative results based on targeted mass spectrometry approach such as MRM
(Multiple Reaction Monitoring) and PRM (Product Reaction Monitoring) analysis.
This method utilizes internal standards (IS) in the form of isotopically labeled surrogate peptides for each target.
We have developed and provide a reproducible results that meets the validation guidelines outlined by the Ministry of Food and Drug Safety.
This method ensures high reproducibility with a coefficient of variation (CV) of less than 15%.
quality control of protein therapeutics (HCP), absolute quantification of proteins within samples, biomarker validation
We are capable of verifying the purity during the separation and purification of monoclonal antibody drugs and cell-based therapeutics.
Analysis package: Mass spectrometry-based analysis method
(Semi, Absolute quantification) as an alternative to ELISA analysis
Single-cell technologies can serve as a starting point for the development of
effective personalized therapies and cures for diseases. In particular,
mass spectrometry-based single-cell proteomics provides unbiased results.
Bertis has introduced Bruker’s timsTOF SCP system, which provides meaningful
results even in true single-cell level.
drug target discovery, spatial biology
Lipids, consisting of over 4,000 diverse compounds, are present in various tissues and cellular compartments of the human body. They are being applied not only in cancer research but also in metabolic disease studies. The PASS service provides identification and quantification of lipids in samples using representative standard substances. Additionally, we provide profiling results of exosomal lipid composition according to the guidelines of the Ministry of Food and Drug Safety.
quality analysis of new drugs (exosomes), Biomarker discovery